A1166C polymorphism of the angiotensin AT1 receptor (AT1R) gene alters endothelial response to statin treatment

Clinical Chemistry and Laboratory Medicine

Volumn 45, Issue 7, 2007, Pages 839-842

  Kiliszek, Marek ^a,d   Burzyńska, Beata ^b   Styczyński, Grzegorz ^a   Macia̧g, Monika ^b   Rabczenko, Daniel ^c   Opolski, Grzegorz ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b INSTITUTE OF BIOCHEMISTRY AND BIOPHYSICS   (Poland)

^c NATIONAL INSTITUTE OF HYGIENE   (Poland)

^d NONE   (Poland)

Author keywords

Genetic polymorphisms; Statin treatment; Vascular endothelium

Indexed keywords

ALANINE; ANGIOTENSIN 1 RECEPTOR; CHOLESTEROL; CYSTEINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FLUINDOSTATIN; GLYCERYL TRINITRATE; GLYCINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PPHOX22 PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; SIMVASTATIN; THREONINE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ARTERY BLOOD FLOW; ARTERY DILATATION; ARTICLE; BRACHIAL ARTERY; CELL FUNCTION; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG MECHANISM; ENDOTHELIUM CELL; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HYPERCHOLESTEROLEMIA; MALE; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; CORONARY DISEASE; ENDOTHELIUM, VASCULAR; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RECEPTOR, ANGIOTENSIN, TYPE 1; VASODILATION;

EID: 34447277837     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2007.151     Document Type: Article

References (23)

1. Celermajer DS, Sorensen KE, Bull C, Robinson J, Deanfield JE. Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coll Cardiol 1994;24:1468-74.
2. Yataco AR, Corretti MC, Gardner AW, Womack CJ, Katzel LI. Endothelial reactivity and cardiac risk factors in older patients with peripheral arterial disease. Am J Cardiol 1999;83:754-8.
3. Lieberman EH, Gerhard MD, Uehata A, Selwyn AP, Ganz P, Yeung AC, et al. Flow-induced vasodilation of the human brachial artery is impaired in patients less than 40 years of age with coronary artery disease. Am J Cardiol 1996;78:1210-4.
4. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000;87:840-4.
5. Fenster BE, Tsao PS, Rockson SG. Endothelial dysfunction: clinical strategies for treating oxidant stress. Am Heart J 2003;146:218-26.
6. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995;332:488-93.
7. Treasure CB, Klein JL, Weintraub WS, Talley JD, Stillabower ME, Kosinski AS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995;332:481-7.
8. Kiliszek M, Maczewski M, Styczynski G, Duda M, Opolski G, Beresewicz A. Low-density lipoprotein reduction by simvastatin is accompanied by angiotensin II type 1 receptor downregulation, reduced oxidative stress, and improved endothelial function in patients with stable coronary artery disease. Coronary Artery Dis 2007;18:201-9.
9. Landmesser U, Bahlmann F, Mueller M, Spiekermann S, Kirchhoff N, Schulz S, et al. Simvastatin versus ezetimibe. Pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 2005;111:2356-63.
10. Hilgers KF, Langenfeld MR, Schlaich M, Veelken R, Schmieder RE. 1166 A/C polymorphism of the angiotensin II type 1 receptor gene and the response to shortterm infusion of angiotensin II. Circulation 1999;100:1394-9
11. Inoue N, Kawashima S, Kanazawa K, Yamada S, Akita H, Yokoyama M. Polymorphism of the NADH/NADPH oxidase p22 phox gene in patients with coronary artery disease. Circulation 1998;97:135-7.
12. Hingorani AD, Liang CF, Fatibene J, Lyon A, Monteith S, Parsons A, et al. A common variant of the endothelial nitric oxide synthase (Glu298→Asp) is a major risk factor for coronary artery disease in the UK. Circulation 1999;100:1515-20.
13. De Backer G, Ambrosioni E, Bort-Johnsen K, Brotonsh C, Cifkovae R, Dallongeville J, et al. European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2003;24:1601-10.
14. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, et al. Guidelines for the ultrasound assessment of endothelial-dependent flowmediated vasodilation of the brachial artery. J Am Coll Cardiol 2002;39:257-65.
15. Bilsborough W, Green DJ, Mamotte CD, van Bockxmeer FM, O'Driscoll GJ, Taylor RR. Endothelial nitric oxide synthase gene polymorphism, homocysteine, cholesterol and vascular endothelial function. Atherosclerosis 2003;169:131-8.
16. Schneider MP, Erdmann J, Delles C, Fleck E, Regitz-Zagrosek V, Schmieder RE. Functional gene testing of the Glu298Asp polymorphism of the endothelial NO synthase. J Hypertens 2000;18:1767-73.
17. Schachinger V, Britten MB, Dimmeler S, Zeiher AM. NADH/NADPH oxidase p22 phox gene polymorphism is associated with improved coronary endothelial vasodilator function. Eur Heart J 2001;22:96-101.
18. Kurland L, Melhus H, Sarabi M, Millgard J, Ljunghall S, Lind L. Polymorphisms in the renin-angiotensin system and endothelium-dependent vasodilation in normotensive subjects. Clin Physiol 2001;21:343-9.
19. Zhu S, Meng QH. Association of angiotensin II type receptor gene polymorphism with carotid atherosclerosis. Clin Chem Lab Med 2006;44:282-4.
20. Benetos A, Gautier S, Ricard S, Topouchian J, Asmar R, Poirier O, et al. Influence of angiotensin-converting enzyme and angiotensin II type 1 receptor gene polymorphisms on aortic stiffness in normotensive and hypertensive patients. Circulation 1996;94:698-703.
21. van Geel PP, Pinto YM, Voors AA, Buikema H, Oosterga M, Crijns HJ, et al. Angiotensin II type 1 receptor A1166C gene polymorphism is associated with an increased response to angiotensin II in human arteries. Hypertension 2000;35:717-21.
22. Danser AH, Schunkert H. Renin-angiotensin system gene polymorphisms: potential mechanisms for their association with cardiovascular diseases. Eur J Pharmacol 2000;410:303-16.
23. Cameron VA, Mocatta TJ, Pilbrow AP, Frampton CM, Troughton RW, Richards AM, et al. Angiotensin type-1 receptor A1166C gene polymorphism correlates with oxidative stress levels in human heart failure. Hypertension 2006;47:1155-61.